drugset / Trial / NCT04783766

Safety, Tolerability and Pharmacokinetics Study of CK-3773274

NCT04783766

Phase 1 Completed 28 enrolled Corxel Pharmaceuticals Cytokinetics · collab
RandomizedSequentialDouble-blindBasic science

Summary

The purposes of this study are to: 1. Learn about the safety of CK-3773274 after a single dose and multiple doses in Chinese healthy adult subjects. 2. Learn how healthy subjects tolerate CK-3773274 after a single dose and multiple doses. 3. Find out how much CK-3773274 is in the blood after a single dose and multiple doses. 4. Determine the effect of doses of CK-3773274 on the pumping function of the heart. 5. Evaluate the effect CYP2D6 genetic polymorphisms on how the body metabolizes CK-3773274.

Timeline

Start
2021-04-10
Primary completion
2021-08-05
Completion
2021-08-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Aficamten Small molecule 5 mg Oral
Subject Aficamten Small molecule 10 mg Oral
Subject Aficamten Small molecule 20 mg Oral